Aim. To evaluate the efficacy and safety of combination therapy with α1-blocker and phosphodiesterase type 5 inhibitor (PDE5) in patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED).
Materials and methods. The observational multicenter program involving 18 medical institutions in Moscow included 315 men aged 40–65 years with BPH and ED. The inclusion criteria were a total IPSS score more than 8 points, QoL score of more than 3 points and clinical manifestations of ED (≤ 20 points on the IIEF-5 score). All patients received combined pharmacotherapy with Alfuprost® MP 10 mg/day and Viatail® 50 mg/day (if necessary, the dose was increased to 100 mg/day) for 3 months.
Results. The combination therapy showed a high clinical efficiency and a favorable safety profile. Lower urinary tract symptoms improved by more than 60%, QoL increased by 64% and erectile function improved in more than 80% of patients. At the end of treatment, the average patient satisfaction score on the Likert scale was 4.2 (high and very high satisfaction), while doctor’s satisfaction with the clinical response of patients to the treatment was 4.35 points, which also corresponds to high and very high efficacy of therapy.
Conclusion. Combination of Alfuprost® MP 10 mg/day and Viatail® 50 mg/day (100 mg, if necessary) can be considered as one of the best options for non-surgical treatment of patients with BPH and ED.

Keywords: α1-blocker, benign prostatic hyperplasia, phosphodiesterase type 5 inhibitors, erectile dysfunction